Sanofi SA (NYSE:SNY) was the target of unusually large options trading on Thursday. Stock traders purchased 10,896 call options on the stock. This is an increase of approximately 1,234% compared to the typical volume of 817 call options.
SNY stock traded down $0.07 during trading on Friday, hitting $40.15. The stock had a trading volume of 1,058,021 shares, compared to its average volume of 1,283,014. Sanofi has a 1-year low of $38.14 and a 1-year high of $50.65. The company has a market capitalization of $100,875.30, a price-to-earnings ratio of 12.83, a PEG ratio of 2.03 and a beta of 0.85. The company has a current ratio of 1.70, a quick ratio of 1.26 and a debt-to-equity ratio of 0.25.
Sanofi (NYSE:SNY) last announced its earnings results on Wednesday, February 7th. The company reported $0.62 earnings per share for the quarter, missing the consensus estimate of $0.69 by ($0.07). The firm had revenue of $8.69 billion during the quarter, compared to analyst estimates of $8.65 billion. Sanofi had a net margin of 23.25% and a return on equity of 24.30%. The company’s revenue for the quarter was down 2.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.25 EPS. research analysts predict that Sanofi will post 3.36 earnings per share for the current year.
The firm also recently declared an annual dividend, which will be paid on Monday, June 4th. Shareholders of record on Thursday, May 10th will be issued a $1.8609 dividend. This is a boost from Sanofi’s previous annual dividend of $1.58. The ex-dividend date of this dividend is Wednesday, May 9th. This represents a yield of 4.72%. Sanofi’s payout ratio is 35.14%.
A number of institutional investors and hedge funds have recently bought and sold shares of SNY. Bank of Nova Scotia Trust Co. purchased a new stake in Sanofi in the 3rd quarter valued at about $125,000. We Are One Seven LLC purchased a new stake in Sanofi in the 4th quarter valued at about $160,000. Bronfman E.L. Rothschild L.P. grew its holdings in Sanofi by 46.0% in the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 4,325 shares of the company’s stock valued at $186,000 after buying an additional 1,362 shares during the period. SeaCrest Wealth Management LLC purchased a new stake in Sanofi in the 4th quarter valued at about $200,000. Finally, Synovus Financial Corp purchased a new stake in Sanofi in the 4th quarter valued at about $224,000. Institutional investors own 8.98% of the company’s stock.
Several research firms have recently issued reports on SNY. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $45.00 price target (down previously from $50.00) on shares of Sanofi in a research note on Thursday, February 8th. ValuEngine downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research downgraded Sanofi from a “hold” rating to a “sell” rating in a research note on Wednesday, February 14th. TheStreet downgraded shares of Sanofi from a “b-” rating to a “c+” rating in a research note on Tuesday, February 13th. Finally, Liberum Capital raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Friday, March 23rd. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $49.33.
WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/07/sanofi-target-of-unusually-high-options-trading-sny.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.